ArticleRheumatology international2010
Regulation of TNFalpha and IL1beta in rheumatoid arthritis synovial fibroblasts by leukotriene B4.
Article in Rheumatology international, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 36 citations in OpenAlex.
- Gut microbiota in chronic inflammation: the interplay with lipid mediators.Gut microbes · 2026Review
- Current trends in epigenetic, cellular and molecular pathways in management of rheumatoid arthritis.Inflammopharmacology · 2023Review
- Lipid metabolism and rheumatoid arthritis.Frontiers in immunology · 2023Review
- Lipidomic Profiling in Synovial Tissue.Frontiers in medicine · 2022Review
- Lipid Metabolism Profiles in Rheumatic Diseases.Frontiers in pharmacology · 2021Review
- Anti-Inflammatory Activity of a Polymeric Proanthocyanidin from Serjania schiedeana.Molecules (Basel, Switzerland) · 2017Article
- In vivo amelioration of endogenous antitumor autoantibodies via low-dose P4N through the LTA4H/activin A/BAFF pathway.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- G protein-coupled receptors as targets for anti-diabetic therapeutics.Nature reviews. Drug discovery · 2016Review
- Persisting eicosanoid pathways in rheumatic diseases.Nature reviews. Rheumatology · 2014Review
- 5-Lipoxygenase inhibitors attenuate TNF-α-induced inflammation in human synovial fibroblasts.PloS one · 2014Article
- The interrelationship between leukotriene B4 and leukotriene-A4-hydrolase in collagen/adjuvant-induced arthritis in rats.BioMed research international · 2014Article
- Interactions between α-tocopherol, polyunsaturated fatty acids, and lipoxygenases during embryogenesis.Free radical biology & medicine · 2014Review
- Leukocytes regulate retinal capillary degeneration in the diabetic mouse via generation of leukotrienes.Journal of leukocyte biology · 2013Article
- Logistic regression analysis of damp-heat and cold-damp impeding syndrome of rheumatoid arthritis: a perspective in Chinese medicine.Chinese journal of integrative medicine · 2012Article
- Herbal medicinal products target defined biochemical and molecular mediators of inflammatory autoimmune arthritis.Bioorganic & medicinal chemistry · 2011Review
- Joint tissues amplify inflammation and alter their invasive behavior via leukotriene B4 in experimental inflammatory arthritis.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
- Scientific validation of anti-arthritic effect of Kashayams - A polyherbal formulation in collagen induced arthritic rats.Journal of Ayurveda and integrative medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arachidonic acid metabolites, such as leukotriene B4 (LTB4), are known to play an important role in pathogenesis of rheumatoid arthritis (RA). Apart from leukocytes, RA synovial fibroblasts (RASF) produce a broad array of inflammatory mediators to recruit, retain and activate immune cells and resident mesenchymal cells in the joints to promote ongoing inflammation and tissue destruction. To determine how LTB4 may contribute to this process, RASF was cultured from synovial tissues collected from RA patients undergoing total knee replacement. The level of LTB4 in culture medium was determined using ELISA, and expression of LTB4 receptors (BLT1 and BLT2) by RT-PCR. In the presence of exogenous LTB4, mRNA and protein levels of tumor necrosis factor-alpha (TNFalpha) and interleukin 1beta (IL1beta) were determined by real-time PCR and ELISA. Furthermore, we examined the effects of leukotrienes synthesis inhibitors, MK886 and bestatin, on mRNA and protein levels of TNFalpha and IL1beta in RASF. We found that LTB4 was present at a low concentration in the culture medium of RASF, and the major LTB4 receptor expressed in RASF was BLT2. LTB4 synthesis was activated by treatment with LIT (LPS, ionomycin and thapsogargin), and suppressed by MK886 and bestatin. Exogenous LTB4 remarkably increased the expression of TNFalpha and IL1beta at both the mRNA level and the protein level. In contrast, MK886 and bestatin significantly inhibited their expression. These data suggested that LTB4 contributed to RA by regulating the expression of TNFalpha and IL1beta in RASF. BLT2 was probably the major receptor mediating such effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.